Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Relispray Nitron is a topical analgesic aerosol spray developed by Midas Care, specifically formulated to provide immediate cryotherapy (cold therapy) for acute pain relief. Marketed as an "ice-cold spray," it is primarily indicated for sports injuries, sprains, strains, and muscle impact injuries. The product works by rapidly lowering the skin temperature upon application, mimicking the physiological effects of an ice pack to reduce localized inflammation, edema, and pain. Its formulation typically includes cooling agents such as menthol, which activates cold-sensitive TRPM8 receptors, and methyl salicylate (derived from wintergreen oil), which provides local anti-inflammatory and analgesic effects by inhibiting cyclooxygenase enzymes. Relispray Nitron is designed for quick absorption and instant symptomatic relief in emergency or athletic settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Relispray Nitron.